This study investigates the treatment of resectable pancreatic cancer. It compares two approaches to chemotherapy: one given before and after surgery, and another given only after surgery.
The study evaluates the effectiveness of chemotherapy in improving overall survival for patients with resectable pancreatic cancer. It looks at how preoperative and postoperative chemotherapy might impact patient outcomes.
- Who can participate: Adults aged 19 to 80 years with resectable pancreatic cancer and good performance status may participate. Key eligibility includes no prior pancreatic surgery or chemotherapy.
- Study details: Participants will receive either chemotherapy before and after surgery or only after surgery.